Nifedipine in the prophylaxis of classic migraine: a crossover, double-masked, placebo-controlled study of headache frequency and side effects.
Twenty-four patients with classic migraine attacks were treated with either nifedipine or placebo for up to 12 weeks. No significant differences were observed between the nifedipine (2.1 +/- 0.2) and placebo (2.3 +/- 0.2) treatment groups in the monthly frequency of headaches. However, the incidence of side effects was significantly greater (p less than 0.001) in the nifedipine (54% of patients) than in the placebo (8% of patients) treatment groups.
McArthur
J C
JC
Department of Neurology, Johns Hopkins Hospital, Baltimore, MD.
Marek
K
K
Pestronk
A
A
McArthur
J
J
Peroutka
S J
SJ
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D008881:Migraine Disorders / Q000503:physiopathology / Q000517:prevention & control*; D009543:Nifedipine / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos
D010919:Placebos; D009543:Nifedipine